The **ACTA Trial of the Year Award** was established in 2016 to recognise and celebrate the outstanding achievements of ACTA Members who advance clinical practice and save or improve the lives of patients every year through investigator-driven clinical trials.

In 2023, ACTA are proud to launch the **ACTA Industry Partnership Award** which will highlight and celebrate commercial and academic investigator collaborations in clinical trials.

We look forward to receiving your nomination.

**THINGS TO KNOW**

* The nomination submission deadline is midnight, Tuesday 6 June 2023
* Please send your nomination/s to: [awards@clinicaltrialsalliance.org.au](mailto:awards@clinicaltrialsalliance.org.au)
* For further information about the awards, please contact ACTA via: +61 3 8639 0770   
  or [awards@clinicaltrialsalliance.org.au](mailto:awards@clinicaltrialsalliance.org.au)
* All winners will be notified by phone and/or email and announced publicly at the National Tribute and Awards Ceremony.
* The National Tribute and Awards Ceremony will be held from held at the International Trials Symposium on 28 November 2023 as part of the Gala Dinner
* Condition of entry – winners are to make themselves available to attend the International Trials Symposium Gala Dinner

**IN THIS DOCUMENT**

**Guidelines**

* ACTA Industry Partnership Award guidelines Page 2
* Announcement of winner(s) and requirements for investigators Page 3
* How to nominate a trial guidelines Page 3

**Nomination form**

* Nomination form – Please complete all sections Page 4-6

**ACTA Industry Partnership AWARD Guidelines**

The **ACTA Industry Partnership Award** will be awarded to a collaboration between a commercial entity[[1]](#footnote-2) and a team of academic investigators who are associated with one or more of a member network (full or associate), clinical quality registry, or trial coordinating centre that have combined to conduct a high-impact clinical trial.

Eligibility criteria:

* **Primary results of the nominated trial should be published published in the 2022 calendar year (electronically or in print)**
* **The academic investigators must be based in Australia or New Zealand and at least some recruitment must have occurred in these countries.**
* **Nominees must have played a major role in the collaborative clinical trial activity, and all joint parties must be disclosed on the application**
* **Nominees will provide a description of how the trial and the involvement of the collaborating companies was vital in addressing a public health question**
* **The nomination will be signed by an industry and academic representative involved in the trial.**

Collaborators may only nominate one trial for consideration for the ACTA Industry Partnership Award in a calendar year. Any trial nominated for an ACTA Industry Partnership Award can also be nominated for other ACTA awards in the same calendar year (using a [separate nomination form available online](https://clinicaltrialsalliance.org.au/events-forums/clinical-trials-2022-national-tribute-and-award-ceremony/)).

A peer-led panelof senior trialists, industry representatives and one consumer representative will review all nominations and judge the trial that is the best demonstration of the following standards[[2]](#footnote-3):

* **The trial addressed a critical gap in the evidence or a significant innovation in healthcare delivery**
* **There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or healthcare delivery**
* **The partnership is exemplary and sets a new benchmark for other partnerships.**

Assessment of the applications will be around the nature of the partnership; however, the judges will also be asked to confirm that the research undertaken in the trial in question was of outstanding quality.

**Prize for the ACTA Industry Partnership Award**

* Invitation to speak at the 2023 ACTA International Clinical Trials Symposium: The Chief Investigator or a representative will receive an invitation to give a presentation on key lessons learned from the trial as well as a complimentary registration to attend the full event. Travel costs will be supported for this speaker.
* An additional complimentary registration for the 2023 ACTA International Clinical Trials Symposium will be given to a member of the winning team.

**Requirements for investigators**

The Chief Investigator or a nominated senior member of the team of academic investigators or network of the winning trial (and wherever possible, each of the named finalists) **must be available to attend the ceremony** to receive the award and to participate in media activities in relation to the awards, including by helping to source trial participants or patients for interview.

**How to nominate a trial**

Any organisation that submits a trial for the ACTA Industry Partnership Award must provide the following:

* **A completed nomination form signed by an industry and academic representative. This will include:**
  + A brief peer summary (approx. one page) describing the trial and why it warrants recognition as ACTA Industry Partnership Award 2023.
  + A brief easy English summary (approx. half page) describing the trial and how the results are likely to impact patients and/or the delivery of healthcare. Easy English summaries should be suitable for publication on the ACTA website and in the general media.
* **A PDF copy of the published paper and any supplementary materials.**

**Nominations will close at midnight, Tuesday 6 June 2023.** No further nominations will be accepted after the deadline.

Please **submit the completed form in Word format**, along with a PDF copy of the trial’s primary results publication and supplementary materials, to: [**awards@clinicaltrialsalliance.org.au**](mailto:awards@clinicaltrialsalliance.org.au)**.**

**NOMINATION FORM**

|  |  |
| --- | --- |
| Scientific name of the trial | Click or tap here to enter text. |
| Short name of the trial | Click or tap here to enter text. |
| Name of the not-for-profit entity that the team of academic investigators are affiliated with | Click or tap here to enter text. |
| Name of the industry organisation | Click or tap here to enter text. |
| Name of the Chief Investigator | Click or tap here to enter text. |
| Email | Click or tap here to enter text. |
| Phone | Click or tap here to enter text. |
| Citation of the publication in which the primary results were reported | Click or tap here to enter text. |
| Date published (electronic or in print) | Click or tap here to enter text. |
| Did this trial receive funding from the Australian Government? If so, please provide the amount and Funding ID number, if relevant | Click or tap here to enter text. |
| Describe the nature and the basic details of the partnership, and outline the public health question the partnership aimed to address | Click or tap here to enter text. |
| Explain how this trial achieved an outcome that would not have been possible if the partnership had not been created | Click or tap here to enter text. |
| Describe how this partnership is exemplary and sets a new benchmark for other partnerships | Click or tap here to enter text. |

|  |
| --- |
| **Peer summary** |
| Please provide a summary (approx. one page) describing the trial and why it warrants recognition of ACTA Industry Partnership Award of the Year. In addition, please address each of the judging criteria:   * The trial addressed a critical gap in the evidence or a significant innovation in healthcare delivery * The quality of the research design, conduct and analysis were outstanding   There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or healthcare delivery. |
| Click or tap here to enter text. |
| **Easy English summary** |
| Please provide a brief easy English summary (approx. half page) describing the trial and how the results are likely to impact patients and/or the delivery of healthcare. This should be suitable for publication on the ACTA website and in the general media. |
| Click or tap here to enter text. |

**A PDF copy of the published paper and supplementary materials is provided with this nomination form.**

**DECLARATION**

|  |  |  |  |
| --- | --- | --- | --- |
| **Trial nominated by (not-for-profit representative)** | | **Trial nominated by (industry representative)** | |
| **Email** | Click or tap here to enter text. | **Email** | Click or tap here to enter text. |
| **Phone** | Click or tap here to enter text. | **Phone** | Click or tap here to enter text. |
| **Signature** | Click or tap here to enter text. | **Signature** | Click or tap here to enter text. |
| **Date** | Click or tap here to enter text. | **Date** | Click or tap here to enter text. |

**Nominations will close at midnight, Tuesday 6 June 2023.** No further nominations will be accepted after this date. Please return your completed form to [awards@clinicaltrialsalliance.org.au](mailto:awards@clinicaltrialsalliance.org.au)

1. includes pharmaceutical, biotechnology, medical technologies, digital medicine companies, and medical device manufacturers. [↑](#footnote-ref-2)
2. The ACTA Board will consider the recommendations of the judging panel in making its decision to announce the recipient(s) of the award. ACTA Board’s decision will be final. [↑](#footnote-ref-3)